Shows / New Retina Radio by Eyetube
New Retina Radio by Eyetube
New Retina Radio is a place to hear stories about retina that are told nowhere else.
Episodes
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab
What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentech/Roche) and are…
New Retina Radio by EyetubeASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally…
New Retina Radio by EyetubeASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders
Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision…
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy
What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis…
- New Retina Radio by Eyetube
The State of Geographic Atrophy Around the Globe: Part 1 of 2
The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic…
- New Retina Radio by Eyetube
The State of Geographic Atrophy Around the Globe: Part 2 of 2
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode…
New Retina Radio by EyetubeDiabetic Retinopathy Severity and Income Status
Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe…
- New Retina Radio by Eyetube
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy
What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this…
- New Retina Radio by Eyetube
GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates
How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In…
New Retina Radio by EyetubePhotobiomodulation for Age-related Macular Degeneration
What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists…
New Retina Radio by EyetubeDuke AVS Clips: PVR, DR, Imaging, and MTM
Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative…
New Retina Radio by EyetubeDuke AVS Clips: Pediatrics, Anesthesia Trends, and AI
Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal…
New Retina Radio by EyetubeDuke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs
During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her…
New Retina Radio by EyetubeARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data
Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a…
New Retina Radio by EyetubeARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline
Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us…
- New Retina Radio by Eyetube
GLP-1s and Risk of Age-Related Ocular Disease
How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined by Alexis Warren…
New Retina Radio by EyetubeFellow Eye RRD Risk per IRIS Registry
Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repaired? What…
New Retina Radio by EyetubeRates of Ocular AEs After Faricimab Injection
What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton…
- New Retina Radio by Eyetube
Treating Geographic Atrophy (GA) In Your Practice
Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen…
- New Retina Radio by Eyetube
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate…
- New Retina Radio by Eyetube
Using OCT Angiography to Distinguish RVO and RAO
How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present…
- New Retina Radio by Eyetube
OCT Angiography in a Real-world CSR Case
What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT…
- New Retina Radio by Eyetube
Switching from Aflibercept to Faricimab in Wet AMD Patients
Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his…
New Retina Radio by EyetubeGA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?
What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani…
New Retina Radio by EyetubeAAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's
How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database…
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?
Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari…
New Retina Radio by EyetubeAAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study…
New Retina Radio by EyetubeAAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD
The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there…
New Retina Radio by EyetubeAAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement
Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss…
New Retina Radio by EyetubeGA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?
We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator…
New Retina Radio by EyetubeNew Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis Prevention
In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study…
- New Retina Radio by Eyetube
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR
Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform…
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO
What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle…
New Retina Radio by EyetubeASRS ’24: C1q Inhibition and Metformin for AMD
Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which…
New Retina Radio by EyetubeNew Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio…
New Retina Radio by EyetubeASRS ’24: PAVILION at 100 Weeks
The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it…
New Retina Radio by EyetubeASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings
Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio…
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC
Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any…
- New Retina Radio by Eyetube
From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME
One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on…
New Retina Radio by EyetubeNew Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic
What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott…
- New Retina Radio by Eyetube
A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World
Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang…
- New Retina Radio by Eyetube
AMD and DME Applications in the Retina Practice: Real-world Data
In the second episode of this 2-part series, moderator Paul Hahn, MD, PhD, and panelists Durga Borkar, MD, MMCi, and Ted Leng, MD, turn to the findings of…
New Retina Radio by EyetubeARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression
Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR…
New Retina Radio by EyetubeNew Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effective for RRD in Patients at Risk for PVR?
How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists…
New Retina Radio by EyetubeARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE
Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as…
New Retina Radio by EyetubeGA Options in Clinical Therapy, Part 2: Real-world Cases in GA
David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of…
New Retina Radio by EyetubeGA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies
Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their…
- New Retina Radio by Eyetube
AMD and DME Applications in the Retina Practice: RCT Comparison
What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the…
- New Retina Radio by Eyetube
The State of Biosimilars: Integration of Biosimilars into a Retina Practice
Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes…
New Retina Radio by EyetubeNew Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT
How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears…
New Retina Radio by EyetubeSuccessful Management of Vitreous Opacities
Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past…
New Retina Radio by EyetubeNew Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery
Do the status of the fovea and/or the timing of surgery affect visual outcomes following RRD repair? Join New Retina Radio Journal Club host Lediana Goduni…
- New Retina Radio by Eyetube
The State of Biosimilars: How We Got Here and What It Means for Practice
Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might…
New Retina Radio by EyetubeCherchez la Femme Revisited
The field of retina has made significant strides when it comes to diversity, equity, and inclusion since Julia A. Haller, MD, penned her inspirational 2015…
New Retina Radio by EyetubeAAO ’23: Downward Trends in Reimbursement and ChatGPT in the Retina Clinic
Reimbursements for vitreoretinal surgery have plummeted in the past decade. How dire is the situation? John Thompson, MD, updates listeners on the trends in…
New Retina Radio by EyetubeNew Retina Radio Journal Club: Intentional Suspension of Therapy in Wet AMD
What are the consequences to intentional suspension of anti-VEGF therapy in wet AMD patients? Join moderator Sruthi Arepalli, MD, and panelists Rebecca Soares…
New Retina Radio by EyetubeAAO ’23: Real-World Faricimab Patterns and Improving GA Assessments
The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche)…
New Retina Radio by EyetubeNew Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD
They’re here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-Francois Korobelnik, MD, PhD stops by to review the 96-week data from…
New Retina Radio by EyetubeNew Retina Radio Journal Club: Prophylactic Laser for Lattice Degeneration in Fellow Eyes After RRD Repair
How effective is prophylactic laser for preventing fellow eye RT/RRD in patients with lattice degeneration who underwent uncomplicated primary RRD repair? NRR…
New Retina Radio by EyetubeNew Retina Radio AAO Late-Breakers: ALTITUDE and DIAMOND
RGX-314 (Regenxbio) could be a one-time gene therapy that addresses diabetic retinopathy. How did it perform in the phase 2 ALTITUDE study? Mark Barakat, MD…